Form 4: Travere Therapeutics CFO Reports Stock Transactions Following FDA Approval of FILSPARI

Travere Therapeutics' CFO, Christopher R. Cline, reports acquisition and disposal of company stock following the FDA's full approval of FILSPARI for IgA Nephropathy.

Summary

• On September 5, 2024, Christopher R. Cline, CFO of Travere Therapeutics, acquired 6,750 shares of common stock upon the vesting of performance restricted stock units (PSUs).
• The PSUs vested because the FDA granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
• On September 9, 2024, Cline sold 2,490 shares at $11.52 per share to cover tax withholding obligations related to the PSU settlement.
• Following these transactions, Cline beneficially owns 74,595 shares of Travere Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the FDA approval of FILSPARI, which triggered the vesting of PSUs. The subsequent stock sale is a standard procedure for covering tax obligations and doesn't necessarily indicate negative sentiment.

Positives

• The vesting of PSUs indicates the achievement of performance criteria, specifically the FDA's full approval of FILSPARI, which is a positive milestone for Travere Therapeutics.

Industry Context

FDA approval of FILSPARI is a significant event for Travere Therapeutics, potentially impacting its market position in the treatment of IgA Nephropathy. Executive stock transactions following such events are common and often related to compensation plans.

Stakeholder Impact

• Shareholders may view the FDA approval of FILSPARI positively.
• Employees who hold PSUs or other equity-based compensation may benefit from the company's success.

Key Dates